drugset
drugset / Trial / NCT01865812

Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis

NCT01865812 ↗

Phase 2 Completed 27 enrolled Intercept Pharmaceuticals
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study was to determine if OCA had an effect on cholesterol levels in the blood in participants with primary biliary cirrhosis (PBC).

Timeline

Start
2013-12-03
Primary completion
2014-08-13
Completion
2016-09-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Obeticholic Acid Small molecule 10 mg Oral

Indications

primary biliary cholangitis